Non-insulin Therapies

In this review, the authors discuss the efficacy and safety of non-insulin therapies, including pramlintide, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 inhibitors (DPP-4), sodium-glucose cotransporter (SGLT1 and SGLT2) inhibitors, metformin, sulfonylureas, and thiazolidinedione’s as add-on therapies to insulin in T1D.

    Related Conference of Non-insulin Therapies

    December 07-08, 2020

    13th World Congress on Endocrinology and Metabolic Disorders

    Auckland, Newzealand
    March 17-18, 2021

    30th European Diabetes Congress

    Barcelona, Spain
    March 22-23, 2021

    Global summit on Diabetes and Endocrinology

    London, UK
    April 13-14, 2021

    World congress on Endocrinology and Metabolic syndrome

    Auckland, Newzealand
    May 10-11, 2021

    30th World Diabetes & Heart Congress

    Singapore, Singapore
    September 02-03, 2021

    5th Annual Congress on Diabetes, Obesity and Its Complications

    Vienna, Australia
    October 18-19, 2021

    2nd Annual Summit on Diabetes and Endocrinology

    Paris, France

    Non-insulin Therapies Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in